Segment Information (Tables)

9 Months Ended

Sep. 30, 2021

Segment Reporting [Abstract]

Schedule of Financial Information by Segment

Financial information by segment for the three months ended September 30, 2021 and 2020 is as follows:

	Three Months Ended September 30, 2021
	Cell Therapy			BioBanking			Degenerative Disease		Other				Total
Net sales	$	-		$	1,343		$	9,279	$	-			$	10,622
Gross profit		-			420			7,891		-				8,311
Direct expenses		22,690			505			2,601		19,613				45,409
Segment contribution		(22,690	)		(85	)		5,290		(19,613	)			(37,098	)
Indirect expenses										(47,996	)	(a)		(47,996	)
Income from operations													$	10,898
(a) Components of other
Change in fair value of contingent consideration liability										(48,549	)
Amortization										553
Total other									$	(47,996	)

	Three Months Ended September 30, 2020
	Cell Therapy			BioBanking			Degenerative Disease			Other				Total
Net sales	$	-		$	1,399		$	1,956		$	-			$	3,355
Gross profit		-			710			1,612			-				2,322
Direct expenses		10,913			806			2,177			5,648				19,544
Segment contribution		(10,913	)		(96	)		(565	)		(5,648	)			(17,222	)
Indirect expenses											(12,416	)	(b)		(12,416	)
Loss from operations														$	(4,806	)
(b) Components of other
Change in fair value of contingent consideration liability											(142,599	)
Impairment of acquired intangible assets											129,400
Amortization											783
Total other										$	(12,416	)

Financial information by segment for the nine months ended September 30, 2021 and 2020 is as follows:

	Nine Months Ended September 30, 2021
	Cell Therapy			BioBanking		Degenerative Disease		Other				Total
Net sales	$	-		$	4,204	$	12,275	$	-			$	16,479
Gross profit					1,986		9,500		-				11,486
Direct expenses		61,082			1,499		6,765		52,453				121,799
Segment contribution		(61,082	)		487		2,735		(52,453	)			(110,313	)
Indirect expenses									(16,205	)	(c)		(16,205	)
Loss from operations												$	(94,108	)
(c) Components of other
Change in fair value of contingent consideration liability									(17,845	)
Amortization									1,640
Total other								$	(16,205	)

	Nine Months Ended September 30, 2020
	Cell Therapy			BioBanking		Degenerative Disease			Other				Total
Net sales	$	-		$	4,213	$	6,822		$	-			$	11,035
Gross profit		-			2,445		4,828			-				7,273
Direct expenses		38,185			1,943		8,635			15,383				64,146
Segment contribution		(38,185	)		502		(3,807	)		(15,383	)			(56,873	)
Indirect expenses										106,107		(d)		106,107
Loss from operations													$	(162,980	)
(d) Components of other
Change in fair value of contingent consideration liability										(26,136	)
Impairment of acquired intangible assets										129,400
Amortization										2,843
Total other									$	106,107